VivoSeq
Oncology

Oropharynx Cancer

19

Pipeline Programs↗

5

Active Trials↗

13

Companies Involved↗

Oropharynx Cancer is an emerging landscape with 19 programs across 13 companies. The most active players are Roche, Teva, Bristol-Myers Squibb. 2 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

64/100

Attrition Rate

26/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 2Teva logo

Teva

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2T

Triax

1 program

Phase 2I

Imclone

1 program

Phase 2A

ALX Oncology Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

62%

Small molecule

13 of 21 classified programs — the dominant modality here.

38%ALL OTHERSMonoclonal antibody629%Protein / enzyme15%Vaccine15%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 21 pipeline programs.

Analysis

Trial Status

19

clinical trials

Completed9 · 47%
Terminated4 · 21%
Recruiting3 · 16%
Active, not recruiting2 · 11%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

19 trials

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
Recruiting·UUniversity of California, San Diego·Phase 2·NCT05787639·29 enrolled
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Recruiting·FFox Chase Cancer Center·Phase 2·NCT05800574·22 enrolled
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Recruiting·—·Phase 2·NCT05388773·150 enrolled
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT06234748·19 enrolled
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 3·NCT01706939·23 enrolled
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03416153·91 enrolled
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00014118
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
Completed·MMayo Clinic·Phase 3·NCT02908477·228 enrolled
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Completed·—·Phase 2·NCT03715946·40 enrolled
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT01084083·90 enrolled
Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01173692·47 enrolled
Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer
Completed·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT00665392·42 enrolled
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
Completed·MMayo Clinic·Phase 1/2·NCT05232851·20 enrolled
Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
Completed·UUNICANCER·Phase 2·NCT03838263·62 enrolled
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
Terminated·National Cancer Institute (NCI)·Phase 2·NCT02917629·6 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)